- Home
- PFN vs PHAR Comparison
PFN vs PHAR Comparison
Compare PFN & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFN
- PHAR
- Stock Information
- Founded
- PFN 2004
- PHAR 1988
- Country
- PFN United States
- PHAR Netherlands
- Employees
- PFN N/A
- PHAR N/A
- Industry
- PFN Finance/Investors Services
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- PFN Finance
- PHAR Health Care
- Exchange
- PFN Nasdaq
- PHAR Nasdaq
- Market Cap
- PFN 636.0M
- PHAR 718.1M
- IPO Year
- PFN N/A
- PHAR N/A
- Fundamental
- Price
- PFN $7.32
- PHAR $11.24
- Analyst Decision
- PFN
- PHAR Strong Buy
- Analyst Count
- PFN 0
- PHAR 3
- Target Price
- PFN N/A
- PHAR $30.00
- AVG Volume (30 Days)
- PFN 331.7K
- PHAR 3.2K
- Earning Date
- PFN 01-01-0001
- PHAR 05-08-2025
- Dividend Yield
- PFN 11.66%
- PHAR N/A
- EPS Growth
- PFN N/A
- PHAR N/A
- EPS
- PFN N/A
- PHAR N/A
- Revenue
- PFN N/A
- PHAR $320,708,000.00
- Revenue This Year
- PFN N/A
- PHAR $13.31
- Revenue Next Year
- PFN N/A
- PHAR $7.68
- P/E Ratio
- PFN N/A
- PHAR N/A
- Revenue Growth
- PFN N/A
- PHAR 24.13
- 52 Week Low
- PFN $5.94
- PHAR $6.65
- 52 Week High
- PFN $7.58
- PHAR $11.86
- Technical
- Relative Strength Index (RSI)
- PFN 59.62
- PHAR 67.56
- Support Level
- PFN $7.12
- PHAR $10.02
- Resistance Level
- PFN $7.35
- PHAR $10.89
- Average True Range (ATR)
- PFN 0.05
- PHAR 0.26
- MACD
- PFN 0.01
- PHAR 0.09
- Stochastic Oscillator
- PFN 84.78
- PHAR 84.08
About PFN PIMCO Income Strategy Fund II
PIMCO Income Strategy Fund II is a closed-ended fixed income mutual fund. The company's primary investment objective is to seek high current income, consistent with the preservation of capital. The fund invests in a range of securities, such as corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, municipal bonds and notes, short-term instruments, sovereign Issues, preferred Securities and others.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.